Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pig erysipelothrix rhusiopathiae antigen and vaccine composition thereof

A technology of Erysipelothrix rhusiopathiae and vaccine composition, which is applied in the direction of viral antigen components, bacterial antigen components, drug combinations, etc., and can solve the problems of lack of immunity and persistence

Inactive Publication Date: 2000-08-09
ZOETIS SERVICE LLC
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The problem is that immunity lacks persistence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] The invention is described in the following illustrative but non-limiting examples. Embodiment 1. Erysipelas rhusiopathiae culture

[0044] Rhusiopathiae strain CN 3342 containing Difco Peptone (concentration is 2.75%), Difco yeast extract (0.55%), Tween 80 (0.2%), K 2 HPO 4 (0.217%) and KH 3 PO 4 (0.061%) (in deionized water) medium. The pH of the medium was adjusted to 7.2 with 5N NaOH. The medium was steam sterilized at a temperature of at least 122°C for 30-90 minutes. After autoclaving, 50% sterile glucose solution was added to a final concentration of 3% (w / v).

[0045] To prepare the working seed culture, first transfer the strain in a cryogenic tube from the frozen storage place (-70°C), thaw it quickly, and transfer it aseptically to the Erlenmeyer flask containing the culture medium. Incubate flasks at 37°C for 12 to 36 hours with constant shaking and check for purity by Gram stain. When a pure culture was found, the culture was mixed with sterile gl...

Embodiment 2

[0048] Prior to harvesting, cultures were checked microscopically for purity, cell morphology, and Gram response. Bacterial growth was monitored by measuring the optical density of the culture at 625 nm. Cultures were harvested when their optical density at 625 nm was 4.0 or greater. Embodiment 2. Preparation of Erysipelothrix rhusiopathiae vaccine

[0049] Formalin solution was added to the cultures at a final concentration of 0.5% (v / v) to inactivate the cultures. Cultures were transferred to sterile tanks and placed in an incubator at 37±2°C for at least 24 hours (up to 60 hours) with constant agitation. Cultures that were not processed immediately were stored at 2-8°C for up to 7 days. Inactivated cultures were clarified by a continuous flow centrifuge. The liquid fraction was retained for further processing and bacteria were discarded.

[0050] In the experiments, a 10-fold concentrate of the culture filtrate of Erysipelothrix rhusiopathiae was made, and the culture ...

Embodiment 3

10

[0056] Satisfactory results in the control group, in which the infection was characterized by hyperthermia (40.9°C [105.6°F] or higher on at least two consecutive days), cultures at necropsy, and / or characteristic after infection with Erysipelothrix rhusiopathiae Clinical symptoms are clearly visible. Clinical features considered characteristic of this disease include sudden death, depression, abdominal and ear congestion, metastatic skin lesions, or joint stiffness and joint-related disorders. Pigs with clinical symptoms but not hyperthermic body temperature were sacrificed and their blood, spleen, and liver were cultured in an attempt to isolate Erysipelothrix rhusiopathiae from them.

[0057] According to Fisher's exact assay, the proportion of pigs determined to be protected or not differed with different vaccines (P<0.05). An optimization control experiment was constructed comparing each dosage group to the control group and comparing each group to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to stabilized antigen compositions of Erysipelothrix rhusiopathiae and vaccine formulations containing such antigen compositions. Antigens of the invention are effective in providing long-term protection against erysipelas in animals.

Description

[0001] Technical Field of the Invention [0002] The present invention relates to antigenic compositions and vaccine formulations for the prevention and treatment of Erysipelothrix rhusiopathiae infection (erysipelas), and methods of making and using these antigenic compositions and vaccine formulations. Background of the invention [0003] Erysipelothrix rhusiopathiae has a worldwide distribution and is of economic importance throughout Europe, Asia, Australia, and South and North America. Pigs aged 3 months to 3 years are most susceptible to erysipelas infection. Infected pigs are often swollen and stiff, unable to gain weight effectively, and their carcasses are often trimmed or handled by inspectors in the packing house. [0004] About 10 years ago, it was shown that the traditional practice of making Erysipelothrix rhusiopathiae vaccine from whole killed cultures was unnecessary. Sterile filtrates can protect pigs and mice against toxic challenges. Subsequent studies p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A61K39/02A61K39/08A61K39/39A61K47/02A61P31/00A61P31/04A61P37/04
CPCA61K2039/55577A61K2039/55566A61K39/08A61P17/00A61P31/00A61P31/04A61P31/12A61P37/04
Inventor D·S·罗伯茨L·A·斯韦林根B·T·苏特
Owner ZOETIS SERVICE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com